JOURNEY MEDICAL CORPOR

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

18 3 2022 12:15:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

17 3 2022 07:30:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the 34th Annual ROTH Conference

09 3 2022 07:30:00 提供 Nasdaq GlobeNewswire

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

11 2 2022 07:00:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

13 1 2022 06:00:01 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

10 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference

07 12 2021 15:05:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Introduces Expanded Board of Directors

29 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Closing of Initial Public Offering

16 11 2021 15:01:00 提供 Nasdaq GlobeNewswire